Gene Mack Appointed Interim CEO of Gain Therapeutics, Inc.
| BioBuzz’s mission is simple: to be more connected. Our regionally-focused storytelling, programs, events and experiences connect, amplify and create impact across the life science workforce in growing biohubs. Submit your People On The Move (free and ongoing) to showcase your company’s growth by promoting your new hires and recent promotions. |
Gain Therapeutics, Inc. a clinical-stage biotechnology company at the forefront of discovering and developing the next generation of allosteric small molecule therapies, has announced a leadership transition. Effective June 25, 2024, Gene Mack, the company’s current Chief Financial Officer, has been appointed as the interim Chief Executive Officer. Mr. Mack will continue to serve as CFO during this interim period.
About Gene Mack
With over 25 years of experience in the life sciences sector, Mr. Mack brings a wealth of expertise in capital markets, investment banking, and corporate finance strategy. He has a proven track record in executing successful M&A and IPO transactions and structuring secondary equity and debt capital instruments for both public and private companies, ranging from early-stage development to commercialization.
Gene Mack’s extensive background in corporate finance and strategic leadership will be invaluable as Gain Therapeutics navigates this transition and continues to drive forward its mission to develop innovative therapies for patients in need.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287 for the treatment of Parkinson’s disease, is currently being evaluated in a Phase 1 clinical trial.
Leveraging AI-supported structural biology, proprietary algorithms, and supercomputer-powered physics-based models, the company’s Magellan™ drug discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Its AI and machine-learning tools and virtual screening capabilities leverage the emerging on-demand compound libraries covering vast chemical spaces of over five trillion compounds to identify and select suitable small molecule hits for experimental validation.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
